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Autotaxin activity predicts 
transplant-free survival in primary 
sclerosing cholangitis
Amandeep K. Dhillon1,2,3, Andreas E. Kremer  4, Martin Kummen  1,2,3, 
Kirsten M. Boberg1,2,5, Ronald P. Oude elferink  6, Tom H. Karlsen1,2,3,5, Ulrich Beuers6, 
Mette Vesterhus1,7,8 & Johannes R. Hov  1,2,3,5
Autotaxin has been associated with liver disease severity and transplant-free survival. this study 
aimed to validate autotaxin as a biomarker in two cohorts of Norwegian large-duct PSC patients, one 
discovery panel (n = 165) and one validation panel (n = 87). Serum activity of autotaxin was measured 
in diluted sera by a fluorometric enzymatic assay. Patients reaching an end-point, liver transplantation 
or death, (discovery panel: n = 118 [71.5%]; validation panel: n = 35 [40.2%]), showed higher autotaxin 
activity compared with the other patients, P < 0.001 and P = 0.004, respectively. Kaplan-Meier 
survival analyses showed a strong association between increasing autotaxin activity and shorter 
liver transplant-free survival (discovery panel: P < 0.001, validation panel: P = 0.001). There was no 
relationship between autotaxin activity and the presence of inflammatory bowel disease or occurrence 
of hepatobiliary malignancy. In a multivariable analysis, high autotaxin activity was associated with an 
increased risk of liver transplantation or death (hazard ratio 2.03 (95% confidence interval 1.21–3.40), 
P < 0.01), independent from Mayo risk score, an in-house enhanced liver fibrosis score and interleukin-8 
in serum. In conclusion, increased serum autotaxin activity is associated with reduced liver transplant-
free survival independent from Mayo risk score and markers of inflammation and fibrosis.
Primary sclerosing cholangitis (PSC) is a progressive inflammatory disease of the intra- and extrahepatic bile 
ducts, leading to strictures, cholestasis, cirrhosis and liver failure. There is no effective medical treatment available 
to retard the progression of PSC. Median time to liver transplantation is 13–21 years1. The disease is complicated 
by cholangiocarcinoma in 10–15% of the patients, which is an important clinical problem with dismal prognosis2.
Pruritus is a common symptom in patients with cholestatic liver diseases, but the underlying mechanisms 
are poorly understood3. Autotaxin is an enzyme that hydrolyzes lysophospholipids into lysophosphatidic acid 
(LPA), which has been identified as a potential mediator of cholestasis-associated pruritus4. LPA is unstable and 
autotaxin activity in serum is used as surrogate marker of LPA levels5. Interestingly, autotaxin is overexpressed in 
some cancers and has been linked to both tumor cell proliferation6,7 and fibrosis8.
The disease activity in PSC patients shows large variations over the disease course, and there are few tools 
available to predict prognosis and measure response to treatment for the individual patient. We have previously 
identified several biomarkers of disease severity and prognosis in PSC reflecting different aspects of the dis-
ease process, like inflammation (IL-8)9, neutrophil activation (soluble CD14)10, fibrosis (enhanced liver fibrosis 
[ELF] score and pro-C3)11 and gut microbial activity12,13. Recently, autotaxin activity was described as a marker 
of severity of liver injury and survival in a study of a single cohort of patients with primary biliary cholangitis 
(PBC) and PSC14. Hence, in the present study we aimed to validate the predictive value of autotaxin activity in 
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two independent Norwegian PSC panels, and explore the role of autotaxin as a potential biomarker for cancer 
development as well as associations with other novel biomarkers.
Patients and Methods
patient population and data collection. In the discovery panel, 165 patients (74% male) with large-duct 
PSC were included, while the validation panel comprised 87 patients with large-duct PSC (82% male). Detailed 
demographic data for both panels can be found in Table 1. The median observation time was 6.58 years (range 
0.01–24.36) from time of sampling for the merged panel.
Diagnosis of PSC was based on typical findings on magnetic resonance cholangiography or endoscopic retro-
grade cholangiography according to established criteria15. Patients were recruited at admission to Oslo University 
Hospital Rikshospitalet in the period from 1992–2006 in the discovery panel and 2008–2011 in the validation 
panel. Regarding the end-point of liver transplantation or death, patients were followed until 31st of December 
2016. Blood samples were included into the Norwegian PSC Research Centre (NoPSC) Biobank (Oslo, Norway). 
The first cholangiography compatible with PSC defined the time of diagnosis. Duration of disease was defined as 
the time from diagnosis to serum sampling. Clinical and demographic information was acquired from patient 
records and research databases, including laboratory data, history of ascites, encephalopathy, variceal bleeding, 
inflammatory bowel disease, colorectal or hepatobiliary malignancy and medication at the time of serum extrac-
tion. Inflammatory bowel disease was diagnosed based on endoscopic and histological findings, according to 
accepted criteria16. Cause of death was extracted from the Cause of Death Registry (Oslo, Norway, reference 
16–0230). Revised Mayo risk score was calculated according to the established algorithm17, in addition to Model 
For End-Stage Liver Disease (MELD) score18 and Aspartate aminotransferase (AST) to Platelet Ratio Index 
(APRI) score, all calculated from data at sample time19.
In-house eLF score. Commercial kits were used to analyze serum levels of TIMP-1 and hyaluronic acid 
(both R&D Systems), and intact N-terminal PIIINP was analyzed by radioimmunoassay (UniQ PIIINP RIA; 
Orion Diagnostica, Espoo, Finland) in frozen serum samples. Inter- and intra-assay coefficients of variation were 
<10%. The algorithm used in the ADVIA Centaur XP ELF test, combining TIMP-1, hyaluronic acid, and PIIINP 
values, was subsequently used to calculate in-house ELF scores (ELF score = 2.278 + 0.851 ln(Chyaluronic acid) 
+ 0.751 ln(CPIIINP) + 0.934 ln(CTIMP1)).
Autotaxin activity assay. Stored sera, from sample time, thawed up to two times were analyzed for aut-
otaxin activity by a fluorometric enzymatic assay. Autotaxin activity was quantified in (at least 20-fold diluted) 
sera. Briefly, serum samples were incubated with a buffer containing 500 mmol/L of NaCl, 5 mmol/L of MgCl2, 
100 mmol/L of Tris (pH = 9.0), and 0.05% Triton X-100 for 60 minutes at 37 °C. Parallel incubations were per-
formed in the presence and absence of 1 mmol/L of LPC (14:0). Subsequently the amount of liberated choline 
Discovery panel Validation panel
Pn = 165 n = 87
Males, n (%) 122 (74) 71 (82)
Age at sampling, years, median (range) 40.98 (13.23–75.50) 38.48 (16.33–63.47) 0.866
Age at diagnosis, years, median (range) 34.06 (13.22–70.09) 34.30 (14.48–62.22) 0.821
PSC duration, years, median (range) 1.08 (−0.15–22.39) 0.72 (−0.59–28.95) 0.328
IBD ever, n (%) 137 (83) 68 (78) 0.037
Follow-up, years, median (range) 4.33 (0.01–24.36) 6.77 (0.04–8.35) 0.335
Liver transplantation as end-point, n (%) 86 (52) 27 (31)
Death as end-point n, (%) 32 (19) 8 (9)
Mayo risk score, median (range) 0.73 (−2.24–5.26) 0.07 (−2.10–3.28) 0.005
ELF-score, median (range) 11.14 (7.67–14.29) 10.67 (7.86–14.11) 0.004
Laboratory data
ALP, U/L, median (range) 567 (70–3100) 230 (51–1459) <0.001
ALT, U/L, median (range) 108 (8.0–780) 88 (14–885) 0.107
AST, U/L, median (range) 100 (8.0–1012) 65 (16–1219) 0.014
Albumin g/L, median (range) 37 (15–50) 41 (24–50) <0.001
Total bilirubin, μmol/L, median (range) 31 (5–464) 20 (4–532) 0.012
Creatinine, μmol/L, median (range) 73 (41–216) 68 (39–90) <0.001
Platelets 109, median (range) 233 (10–879) 285 (56.7–819) 0.008
Other information
Gall bladder cancer, n (%) 1 (0.6) 0
Cholangiocarcinoma, n (%) 18 (11) 8 (9)
Hepatocellular carcinoma, n (%) 2 (1.2) 0
Table 1. Demographic information for the two study panels. ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; ATX, autotaxin; ELF, enhanced liver fibrosis; IBD, 
inflammatory bowel disease; PSC, primary sclerosing cholangitis.
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was determined by enzymatic fluorimetry using choline oxidase (2 U/mL), horseradish peroxidase (1.6 U/mL), 
and homovanillic acid as substrates for peroxidase. After the addition of both enzymes in a buffer (consisting of 
20 mmol/L of CaCl2, 2 mmol/L of HVA, 50 mmol/L of 3-[N-morpholino] propanesulfonic acid [pH = 8.0], and 
0.1% Triton X-100), the increase in fluorescence was monitored at 37 °C using a NOVOstar analyzer (excitation 
320 nm and emission 405 nm; BMG Labtech GmbH, Offenburg, Germany). The (endogenous) amount of choline 
present in the sample without the addition of LPC was subtracted from the amount measured in the presence of 
LPC. Inter-assay variance was less than 15%, and intra-assay variance below 10%.
ethics. The study was carried out in accordance with the Declaration of Helsinki. Written informed consent 
was obtained from all study participants. The Regional Committee for Medical and Health Research Ethics of 
South-Eastern Norway approved the study (reference 2011/2572).
statistical analyses. Data are presented as median (range) unless stated otherwise, except survival (in 
years) which is presented as mean (95% CI). When dichotomizing autotaxin levels in high/low categories, the pre-
viously published cutoff (>7.5 nmol mL−1 min−1) defined by Wunsch et al. was used14. Comparisons were done 
with Mann-Whitney U tests. Liver transplant-free survival was analyzed using Kaplan-Meier plots, and univariate 
and multivariate Cox regression. Variables with P < 0.05 in the univariate analysis were included in the final mul-
tivariate Cox regression model, except age, AST, bilirubin and albumin as they are included in Mayo risk score. 
The MELD score was highly right-skewed even after log-transformation and had a high rate of missing data; thus, 
we used the Mayo risk score in the Cox regression analyses. For correlations, Spearman’s rank correlation test was 
applied. Statistical analyses were performed using SPSS (version 24; SPSS, Inc., Chicago, IL). P-values < 0.05 were 
considered statistically significant.
Results
patient characteristics. There were 165 patients in the exploration panel and 87 in the validation panel. 
74% and 82% of the patients were male, median age at sampling was 41.0 and 38.5 years, 83% and 78% had con-
comitant IBD, 52% and 31% underwent liver transplantation and 32% and 8% died during follow-up in the explo-
ration and validation panel, respectively (Table 1). There was one (0.6%) case of gall bladder cancer and 2 cases of 
hepatocellular carcinoma (1.2%) in the exploration panel, 18 cases (11%) and 8 cases (9%) of cholangiocarcinoma 
in the exploration and validation panel, respectively.
High autotaxin activity is associated with poor prognosis in PSC patients. Mean autotaxin activ-
ity in the merged cohort (n = 252) was 6.8 nmol mL−1 min−1 (standard deviation (SD) 3.7), lower in men, mean 
6.3 nmol mL−1 min−1 (SD 3.0) than in women 8.6 nmol mL−1 min−1 (SD 4.9), P < 0.001. The activity was higher 
than previously reported in both male (2.5 nmol mL−1 min−1, SD 0.7) and female (3.2 nmol mL−1 min−1, SD 1.5) 
healthy controls20, P < 0.001 for both.
During follow-up, 118 (71.5%) and 35 (40.2%) patients reached an end-point, liver transplantation or death, 
in the discovery and validation cohorts, respectively. Patients who reached an end-point during follow-up showed 
higher ATX activity compared with the other patients in both cohorts (P < 0.001 and P < 0.004 in the discovery 
and validation cohort, respectively, Fig. 1a,b).
When stratifying patients according to autotaxin tertiles, there was a strong association between increasing 
autotaxin activity and shorter liver transplant-free survival in both cohorts (Fig. 1c,d). In a previous study, the 
optimal cut-off of autotaxin activity to distinguish patients with a higher risk of end-points was 7.5 nmol mL−1 
min−1 14. Repeating the analysis with this cut-off in the present study yielded similar results, with high auto-
taxin activity concentrations showing reduced liver transplant-free survival compared with the low autotaxin 
group in both cohorts (Fig. 1e,f), discovery panel: 3.90 years [2.30–5.50] vs. 11.79 [9.95–13.63], respectively, 
log-rank P < 0.001; validation panel: 3.83 years [2.62–5.03] vs. 6.80 [6.07–7.53] years, P < 0.001). In a merged 
panel (n = 252) a cut-off of 7.5. nmol mL−1 min−1 yielded a sensitivity of 35% and specificity of 85% for predicting 
liver transplantation or death, with corresponding positive predictive value of 81% and negative predictive value 
of 49%. A dedicated AUROC suggested an optimal cut-off in the present population (using Youden’s index) of 6.4 
nmol mL−1 min−1, with corresponding sensitivity of 54% and specificity of 78%, but with similar positive (79%) 
and negative (52%) predictive values.
Thirty of the patients with death as endpoint died of liver related causes (75.0%), while nine were registered 
with non-hepatic causes of death (22.5%, data missing for n = 1). Re-doing the above analyses with liver-related 
deaths only (censoring patients dying from other causes) did not have major impact on the results (data not 
shown).
Autotaxin and biochemical characteristics. Autotaxin activity was similar in the discovery and vali-
dation panels, mean 6.6 nmol mL−1 min−1 (SD 3.6) and 7.2 nmol mL−1 min−1 (SD 3.8), respectively (P = 0.28). 
Despite some baseline differences (Table 1), we therefore merged the discovery and validation panels to increase 
power when investigating the relationship between clinical and biochemical characteristics.
Significant positive correlations were observed between autotaxin and liver biochemistry (Table 2), with 
the strongest association observed for bilirubin (rho: 0.376, P < 0.001). ALP, AST and INR also correlated with 
autotaxin (rho = 0.16, 0.30, 0.21, respectively, all P < 0.05), as well as C-reactive protein (rho = 0.17, P = 0.011), 
while inverse correlations were noted with creatinine and albumin (rho = −0.323 and −0.404, respectively, both 
P < 0.001).
Patients with impaired liver synthesis function as defined by INR ≥1.2 or Normotest <70 showed increased 
activity of autotaxin compared with patients with normal synthesis function, combined cohort: 7.69 (2.90–23.56) 
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vs. 5.50 (2.35–31.81), P < 0.001 (Fig. 2a). However, autotaxin was a good predictor of liver transplantation or 
death irrespective of liver synthesis function (Fig. 2b).
Autotaxin activity and clinical characteristics. In the merged cohort, 30 (11.9%) PSC patients were 
diagnosed with hepatobiliary malignancy during follow-up. Autotaxin activity was similar in patients who 
developed cancer during follow-up and those who did not (5.49 [2.90–11.35] vs. 5.81 [2.35–31.81], respectively, 
P = 0.42). There was also no difference in patients with and without IBD (5.89 [2.44–31.81] vs. 6.03 [2.44–22.75], 
respectively, P = 0.90), or between the different subtypes of IBD (data not shown). In a small subgroup n = 32, 
severity of disease using the cholangiography-based Amsterdam score was evaluated in a previous study21. 
Patients with advanced PSC had numerically higher autotaxin activity than mild PSC (8.9 vs. 7.7), but this was 
not statistically significant (P = 0.51).
Modest significant correlations were found between autotaxin and PSC duration (rho = 0.184, P = 0.003), and 
clinical risk scores; Mayo risk score (rho = 0.408, P < 0.001) and MELD score (0.233, P = 0.006), also see Table 2. 
Data on ursodeoxycholic acid (UDCA) treatment was available for 86 patients from the validation cohort (99%), 
out of which 35 (41%) were treated at the time of sampling. Patients treated with UDCA had higher autotaxin lev-
els compared to other patients (7.48 [3.83–23.93] vs. 5.50 [2.90–14.25], respectively, P = 0.005). However, Mayo 
risk scores and liver transplant-free survival were not significantly different between patients with and without 
UDCA treatment (Mayo risk score 0.18 (−2.10–3.28) vs −0.04 (−2.09–3.20), respectively P = 0.65, and survival 
5.0 (3.8–6.1) vs. 6.4 (5.6–7.3) years, respectively, P = 0.055).
Figure 1. High autotaxin levels are associated with poor prognosis. Autotaxin levels in PSC patients without/
with end-point, in (a) the discovery panel and (b) validation panel. Autotaxin based liver transplant-free 
survival based on tertiles of autotaxin activity in (c) the discovery panel, and (d) the validation panel. Poorer 
prognosis in patients with high autotaxin activity levels (>7.5 nmol mL−1 min−1 as defined by Wunsch et al.14), 
in (e) the discovery panel, P < 0.001, and (f) and validation panel, P < 0.001. ATX, autotaxin; PSC, primary 
sclerosing cholangitis. Data in (a) and (b) shown as median (min-max).
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Autotaxin activity and new biomarkers of inflammation and fibrosis in PSC. Recent studies have 
suggested that markers of inflammation (IL-8) and liver fibrosis (ELF test) predict liver transplant-free survival 
in PSC11,21,22. Data on IL-8 and an in-house enhanced liver fibrosis score (ELF-score) were available from the 
previous studies21,22, and both correlated with autotaxin activity (Fig. 3). There was a correlation between IL-8 
and the in-house ELF-score (rho: 0.656, P < 0.001), autotaxin and IL-8 (rho: 0.427, P < 0.001) and autotaxin- 
and ELF-score (rho: 0.481 P < 0.001). When dividing ELF and IL-8 in high and low by median, and autotaxin in 
high and low by a cut-off at 7.5 nmol mL−1 min−1, as defined by Wunsch et al.14, high levels were associated with 
reduced liver transplant-free survival for all markers (Fig. 4). Re-doing these analyses with liver-related deaths 
only, did not influence the results (data not shown).
Notably, Mayo risk score had a better ability to discriminate patients with and without liver transplantation 
or death during follow-up (AUC 0.81 vs. 0.66, P < 0.001, Fig. 5a). The same was apparent for in-house ELF (AUC 
0.79, P < 0.001), but not IL-8 (AUC 0.71, P = 0.25), see Fig. 5b. However, when analyzed using Cox regression, 
high autotaxin as defined by the validated cut-off 7.5 nmol mL−1 min−1 was also associated with an increased risk 
of liver transplantation or death, independent from Mayo risk score, the in-house ELF score and IL-8 (HR 2.03 
(95%CI 1.21−3.40), P = 0.007), see Table 3. Adding disease panel (discovery or validation) as covariate, or doing 
analyses on liver-related deaths only, did not influence the results (data not shown).
Discussion
In this cross-sectional study of autotaxin activity in two independent cohorts of PSC patients, we found a strong 
correlation between increasing autotaxin and shorter liver transplantation free survival. Autotaxin activity cor-
related with disease severity, as measured by Mayo risk score, but there was no association with IBD or cancer. 
Autotaxin correlated moderately with new biomarkers in PSC, including IL-8 and ELF-score, but in multivariate 
analyses high autotaxin was an independent predictor of liver transplant-free survival.
A key observation in the present study is that we show in two independent cohorts of in total 252 large-duct 
PSC patients that high autotaxin activity is associated with reduced liver transplant-free survival with a moderate 
HR of 2.0 in multivariable regression, corroborating a previous finding by Wunsch et al., who investigated auto-
taxin in 115 PSC patients14. Similar correlations between autotaxin activity and liver biochemistries and clinical 
parameters like Mayo risk score and MELD score were also seen. This highlights autotaxin activity as a biomarker 
of potential clinical value, in particular in combination with other markers. Its relationship with disease activity 
and response to treatment in drug trials should clearly be investigated to define its utility, in line with recent trials 
investigating markers of fibrosis23,24.
The mechanisms causing elevated autotaxin activity in PSC are not clear. Autotaxin has been shown to pre-
dict survival, disease stage and cirrhosis also in non-cholestatic conditions8,25, while the value of autotaxin as 
a serum marker of fibrosis varies between phenotypes, being a better predictor in viral hepatitis compared to 
non-alcoholic fatty liver disease26. In other studies of viral hepatitis, autotaxin also correlates with liver stiffness 
measured with transient elastography27. Autotaxin has also been reported to inversely correlate with albumin lev-
els in chronic liver diseases7,28, in line with the present data. Mechanistic studies of autotaxin in PSC are scarce. In 
murine models of fibrosis, increased autotaxin expression in hepatocytes has been observed both after liver injury 
caused by carbon tetrachloride and after viral infection29. Genetic or pharmacological inhibition of autotaxin 
subsequently reduced liver fibrosis in the model, suggesting a direct link to fibrosis. However, whether hepatocyte 
expression can account for the increased autotaxin activity observed during cholestasis and cholestatic pruritus 
in PSC is not known. The negative correlation between autotaxin activity and albumin on the one hand, and 
positive correlation with INR on the other hand suggest that autotaxin activity is not affected by liver synthesis 
function. We also make the novel observation that autotaxin activity only moderately correlates with the new 
PSC biomarkers IL-8 and an in-house ELF, whereas autotaxin activity still independently predicts survival. This 











Mayo risk score 0.408 <0.001
MELD 0.233 0.006
APRI 0.355 <0.001
Table 2. Correlations between ATX activity and biochemical markers and clinical risk scores in the merged 
cohort (n = 252). APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; ALP, alkaline phosphatase; CRP, C–reactive protein; INR, international 
normalized ratio; MELD, model for end-stage liver disease.
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fibrosis. Biomarkers of inflammation, fibrosis and pruritus might independently predict prognosis and underline 
the potential utility of multi-marker panels to account for the complexity of PSC. This should be investigated in 
subsequent studies.
Another important observation in the present study is the lack of correlation between autotaxin and biliary 
tract cancer. This is contradictory to studies describing an emerging role of LPA and autotaxin in malignant dis-
eases6, e.g. hematological malignancies30 and pancreatic cancer31. Autotaxin has been proposed to be an impor-
tant mediator in cancer cell growth and metastasis6. It has also been speculated that it is a link between liver 
disease and hepatocellular carcinoma29,32, but data from human studies are conflicting33. Little data is available on 
cholangiocarcinoma (CCA), and there were no signs of association between autotaxin and biliary cancer in our 
cohort. One possible explanation is if autotaxin only reflects the presence of tumor without being able to predict 
later tumor development. Still, the observation contrasts other novel PSC biomarkers, which seem CCA-related. 
Examples include associations observed between CCA in PSC and elevated ELF22, increased soluble CD1410 
and increased prevalence of IgA anti-GP234, providing further evidence of unique characteristics of autotaxin as 
biomarker.
A peculiar observation was the increased autotaxin activity observed in PSC patients receiving treatment 
with UDCA. Importantly, data on UDCA use was only available in the smaller validation cohort (n = 87) and an 
association does not imply causation. In the study by Wunsch et al. autotaxin activity was higher in PBC patients 
who did not respond to UDCA treatment, compared to other patients14. It has been hypothesized that the lack 
of response to UDCA in some PBC patients may indicate a failure to upregulate alk-SMase, another nucleotide 
pyrophosphatase/phosphodiesterase (NPP) enzyme similar to autotaxin, by UDCA in these patients, leading to 
increased levels of autotaxin35. A more likely hypothesis explaining increased autotaxin activity in UDCA-treated 
PSC patients in the present study may be that PSC patients in Norway usually receive UDCA only on specific 
indication, i.e. flares, pruritus or gallstones, and it may be that patients receiving UDCA had more pruritus or 
Figure 2. High autotaxin levels are associated with poor prognosis irrespective of liver synthesis function. (a) 
In the combined cohort, patients with impaired liver synthesis function (defined as INR ≥ 1.2 or Normotest < 
70) showed higher autotaxin-levels compared to patients with normal liver synthesis function (INR < 1.2 or 
Normotest ≥ 70). (b) Survival curves for patients with normal and impaired liver synthesis function, separated 
by high/low autotaxin levels (>or ≤7.5 nmol mL−1 min−1 as defined by Wunsch et al.14). ATX, autotaxin 
activity; INR, international normalized ratio. Data on INR and Normotest missing for n = 43 in the combined 
cohort. Data in (a) shown as median (max-min).
Figure 3. Relationship between autotaxin and markers of inflammation and fibrosis. (a) Scatterplot of 
autotaxin and the inflammation marker IL-8. (b) Scatterplot of autotaxin and an in-house ELF score. IL, 
interleukin; ELF, enhanced liver fibrosis.
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even more serious disease. However, it should be noted that measures of disease severity were not convincingly 
different in patients with and without UDCA (Mayo risk score and liver transplant-free survival).
The strengths of the present study are the large sample size, the inclusion of a validation cohort, and the long 
follow-up period, although the cross-sectional design makes us unable to make assumptions about cause end 
Figure 4. Autotaxin and other established biomarkers in PSC. High autotaxin levels (>7.5 nmol mL−1 min−1 as 
defined by Wunsch et al.14) are associated with poor survival in subgroups with both (a) low IL-8 values, and (b) 
high IL-8 values (divided by median). Similar, high autotaxin levels are associated with reduced liver transplant-
free survival irrespective of (c) low ELF score or (d) high ELF-score (divided by median). ATX, autotaxin; ELF, 
enhanced liver fibrosis; IL, interleukin.
Figure 5. Comparison of autotaxin and other biomarkers in PSC. (a) Mayo risk score had a better ability to 
discriminate patients with and without liver transplantation or death during follow-up (AUC 0.81 vs. 0.66, 
P < 0.001), as had bilirubin (AUC 0.77 vs. 0.66, P < 0.001), while Mayo risk score and bilirubin were similar 
(P = 0.07). The same was apparent for the in-house ELF score (AUC 0.79, P < 0.001) but not IL-8 (AUC 0.71, 
P = 0.25) (panel b). AUC, area under the receiver operating characteristic curve; ELF, enhanced liver fibrosis; IL, 
interleukin; PSC, primary sclerosing cholangitis.
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effect, which could be improved by repeated sampling during disease activity or after endoscopic intervention. 
The inclusion from a tertiary care center suggest that the patients have a more severe phenotype than the general 
population. The limitations also include missing data for some covariates, reducing the number of patients in the 
multivariate analyzes. We lack data on pruritus, a possible key confounder. There is also a possibility that patients 
included in the discovery and validation panels could have inherent differences in liver transplantation-free sur-
vival due to changes in clinical practice which could introduce a bias, but adding cohort as covariate did not 
influence the effect of autotaxin. Despite these limitations, it is reasonable to firmly conclude that increased serum 
autotaxin activity is associated with reduced liver transplant-free survival in PSC patients. This association seems 
to be independent from Mayo risk score and markers of inflammation and fibrosis, and with no relationship with 
cholangiocarcinoma development. Autotaxin is therefore an interesting candidate as clinical biomarker, which 
should be prioritized for follow-up in prospective and interventional studies.
Data Availability
The dataset used in the present study is available from the corresponding author on reasonable request.
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